Yes, the high rollover does suggest no safety issues and hopefully ticks that box amongst the FDA criteria, but it doesn’t improve my “confidence” of efficacy and a successful P3 result. Lilac dropout rates would be great to know, so my “confidence” is supported by our ability to match P2 results (with better knowledge and larger cohort), Lilac 2 centres still opening and as Little T states; the impressive spend Acadia have put on the table.
Yes, the high rollover does suggest no safety issues and...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |